July 9, 2020 / 12:02 PM / in a month

BRIEF-Enanta Pharmaceuticals Announces Clinical Trial Progress For EDP-514

July 9 (Reuters) - Enanta Pharmaceuticals Inc:

* ENANTA PHARMACEUTICALS ANNOUNCES CLINICAL TRIAL PROGRESS FOR EDP-514, ITS LEAD CORE INHIBITOR FOR HEPATITIS B VIRUS

* ENANTA PHARMACEUTICALS ANNOUNCES CLINICAL TRIAL PROGRESS FOR EDP-514, ITS LEAD CORE INHIBITOR FOR HEPATITIS B VIRUS

* ENANTA PHARMACEUTICALS INC - INITIATED PHASE 1B STUDY EVALUATING EDP-514 IN VIREMIC HBV PATIENTS; PRELIMINARY DATA ANTICIPATED IN 1H 2021

* ENANTA PHARMACEUTICALS INC - RESUMED PHASE 1B STUDY ASSESSING SAFETY AND ANTIVIRAL ACTIVITY OF EDP-514 IN NUC-SUPPRESSED HBV PATIENTS

* ENANTA PHARMACEUTICALS INC - PHASE 1B STUDY OF EDP-514 IN NUC-SUPPRESSED HBV PATIENTS, TOPLINE RESULTS ANTICIPATED IN 2Q 2021

* ENANTA PHARMACEUTICALS INC - EDP-514 WAS WELL TOLERATED WITH A FAVORABLE SAFETY PROFILE

* ENANTA PHARMACEUTICALS INC - NO PATIENTS DISCONTINUED EDP-514 DUE TO AN ADVERSE EVENT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below